Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

OcellO announces deal with Merus
May 2019
SHARING OPTIONS:

LEIDEN, the Netherlands—OcellO B.V., a contract research organization offering 3D cell-based assay services for drug discovery to the pharmaceutical industry, has entered an agreement to provide in-vitro research services to Merus N.V., a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, for Merus’ MCLA-158 Biclonics program and other undisclosed Biclonics discovery programs. Pursuant to the agreement, OcellO will provide €1 million of services to Merus over a period of two years. MCLA-158 is in Phase 1 development in patients with solid tumors, with an initial focus on metastatic colorectal cancer. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptors (EGFR).

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.